
Immgolis: First Interchangeable Biosimilar to Simponi
Analyze the FDA approval of Immgolis (golimumab-sldi), the first interchangeable Simponi biosimilar. Learn how auto-substitution impacts rheumatology care.
IntuitionLabs is now a member of the Claude Partner Network – AI training and upskilling with Claude for pharma and biotech. Book a call.

Analyze the FDA approval of Immgolis (golimumab-sldi), the first interchangeable Simponi biosimilar. Learn how auto-substitution impacts rheumatology care.
© 2026 IntuitionLabs. All rights reserved.